Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INOTUZUMAB OZOGAMICIN Cause Hypotension? 35 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 35 reports of Hypotension have been filed in association with INOTUZUMAB OZOGAMICIN (Besponsa). This represents 1.5% of all adverse event reports for INOTUZUMAB OZOGAMICIN.

35
Reports of Hypotension with INOTUZUMAB OZOGAMICIN
1.5%
of all INOTUZUMAB OZOGAMICIN reports
5
Deaths
26
Hospitalizations

How Dangerous Is Hypotension From INOTUZUMAB OZOGAMICIN?

Of the 35 reports, 5 (14.3%) resulted in death, 26 (74.3%) required hospitalization, and 6 (17.1%) were considered life-threatening.

Is Hypotension Listed in the Official Label?

Yes, Hypotension is listed as a known adverse reaction in the official FDA drug label for INOTUZUMAB OZOGAMICIN.

What Other Side Effects Does INOTUZUMAB OZOGAMICIN Cause?

Death (253) Febrile neutropenia (230) Venoocclusive liver disease (229) Neoplasm progression (158) Pyrexia (151) Off label use (146) Sepsis (119) Venoocclusive disease (109) Thrombocytopenia (108) Platelet count decreased (107)

What Other Drugs Cause Hypotension?

SACUBITRIL\VALSARTAN (11,718) AMLODIPINE (6,504) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (4,694) FUROSEMIDE (4,468) TREPROSTINIL (4,412) METOPROLOL (3,213) RITUXIMAB (3,208) METFORMIN (3,116) LENALIDOMIDE (2,920) ACETAMINOPHEN (2,817)

Which INOTUZUMAB OZOGAMICIN Alternatives Have Lower Hypotension Risk?

INOTUZUMAB OZOGAMICIN vs INSULIN INOTUZUMAB OZOGAMICIN vs INSULIN ASPART INOTUZUMAB OZOGAMICIN vs INSULIN ASPART\INSULIN DEGLUDEC INOTUZUMAB OZOGAMICIN vs INSULIN BEEF INOTUZUMAB OZOGAMICIN vs INSULIN DEGLUDEC

Related Pages

INOTUZUMAB OZOGAMICIN Full Profile All Hypotension Reports All Drugs Causing Hypotension INOTUZUMAB OZOGAMICIN Demographics